click to show more information

click to hide/show information About your Search

20130318
20130326
Search Results 0 to 2 of about 3
and built up a cash horde. 92% of their available days this year are covered by more defensive one- to two-year time charter agreements. these things allow the company to hold up much better than it's competitors. even though i think the dry bulk industry might be bottoming, it's still bad enough that i want to stick with the safest player. diana, best of breed. you know how we always like best of breed. nothing's changed in eight years. beyond that looking into 2014, management is somewhat shifted to somewhat shorter duration times. that's good. they think rates are going higher. so they locked in rates when they could, and now they think it's going higher. meanwhile diana's used the weakest in the dry bulk market. buying ships at ultralow prices buying at a time when no one else can. why? because they kept relatively clean balance sheet. company can purchase $900 million worth of ships. and as day rates recover for dry bulk, the value of those ships will increase dramatically. if secondhand ships return to the reversion to the mean, that would be 77% higher than where they are now. so th
in the world. as bristol-meyers is your classic defensive big pharma stock, company is going to keep growing no madder how badly the europeans screw up things because people always need their medicine. frankly, i think it's accelerating its growth. it's time to update this dictum to keep up with the times, old dog, new tricks. the big pharma stocks have been on a real roll lately. i like before it toll myers we owe it for our charitable trust. when i started screaming what that had to do with the price-to-ratios, it was the heyday when the major companies were growth juggernauts and their stocks were valued accordingly. let's take 1998, your typical big pharma stock traded 30 to 40 times earnings. these days they trade in the low teens or even lower. many trade like fixed income vehicles. most of the huge blockbuster drugs from the '90s have gone off patent. they lost that spark of innovation that made their stocks such power houses back in days of yore. so all this week, i want to go where the innovation is. i want to find the companies that could be the next gigantic pharma names. some alr
, with fixodent. the adhesive helps create a food seal defense for a clean mouth and kills bacteria for fresh breath. ♪ fixodent, and forget it. >>> >>> last friday we looked back at the eight best performing stocks since "mad money" went on the air, screening out the ones too small to talk about on television. you know what, two out of the top eight stocks were orphan drug makers, companies that development treatments for ultra rare diseases. i'm a regular daddy war bucks in the biotech sector and tonight i want to talk about an orphan drug player that really worked today. so thrilled we're going to have them on because you could tell from the get-go it is big. nps pharmaceutical, a lead drug for short-bowel syndrome, a rare condition where patients need to be fed intravenously for 10 to 12 hours a day because their intestines cannot properly absorb so they cannot lead normal lives along with another couple interesting drugs. nps is buying back the worldwide marketing rights from at that deada pharmaceutical, approved in europe but controlled the distribution and weren't doing anything wit
Search Results 0 to 2 of about 3